Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRKAd5 HIV-1 gag vaccine
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The MRKAd5 HIV-1 gag vaccine is an investigational therapeutic and preventive DNA vaccine developed for the prevention of human immunodeficiency virus type 1 (HIV-1) infection. It uses a replication-incompetent recombinant adenovirus serotype 5 (Ad5) vector to deliver the near-consensus clade B *gag* gene from HIV-1 into host cells, aiming to elicit strong cellular immune responses against the virus[1][6]. The primary mechanism involves stimulating cytotoxic T lymphocyte (CTL) responses specific to the Gag protein of HIV-1. Developed by Merck, this candidate was evaluated in multiple international clinical trials for safety and immunogenicity. While it induced robust immune responses in healthy volunteers across diverse geographic regions, it ultimately failed to demonstrate efficacy in preventing HIV acquisition or reducing viral load in large-scale efficacy trials[2][4]. The most common adverse events were mild-to-moderate injection site reactions and flu-like symptoms[1].
- Other names
- monovalent MRKAd5 HIV-1 gag vaccine
02
Targets
Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on MRKAd5 HIV-1 gag vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRKAd5 HIV-1 gag vaccine.